What are the differences in risks of adverse pregnancy outcomes based on the level of pre-pregnancy specialist mental health care?

The evidence on the effects of maternal mental health illnesses on increased risk of adverse obstetric and neonatal outcomes.

Boehringer Ingelheim, Zealand’s positive Phase 2 MASH fibrosis data ‘unintentionally’ released

Boehringer Ingelheim and Zealand Pharma’s survodutide has improved liver scarring in a Phase 2 test in patients with metabolic dysfunction-associated steatohepatitis, or MASH, according to

June 7, 2024

DocMorris receives gematik approval for simple digital e-prescription redemption via health card – Biotech Investments

DocMorris AG / Key word(s): Market Launch 10-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

April 11, 2024

Simcere Zaiming and TargetRx sign deal for TGRX-326’s rights

The asset has potential in treating non-small cell lung cancer patients with ALK/ROS1 fusion genes and resistance to multiple ALK mutations. Credit: JOURNEY STUDIO7/Shutterstock. Simcere

September 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.